This site is intended for health professionals only
Wednesday 28 September 2016 Instagram
Share |

Rimonabant and type 2 diabetes: results of the RIO study

Rimonabant and type 2 diabetes: results of the RIO study

Diabetes

Rimonabant is a cannabinoid receptor antagonist that has been licensed as an antiobesity drug. While more long-term studies are needed before definitive recommendations can be made for its use, it has been thought that it might have  a role in obese or overweight people with type 2 diabetes. The RIO-Diabetes study aimed to assess just that.
 
Peter Burrill
BPharm(Hons),  MRPharmS DipPresSci FCPP FFPMM

Specialist Pharmaceutical Adviser for Public Health

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?